While Berg et al. found that classical CD16 negative monocytes can predict future CV risk in nonuremic population [30], some authors found that intermediate CD14++CD16+ monocytes predict CV events in CKD patients [31, 32]. The gene discussed is CD14; the disease is chronic kidney disease.